Answers are grounded in this paper and cite their sources.
Background The composite endpoint for liver surgery (CELS) was developed to predict surgery-related mortality and to improve the design of clinical trials in liver surgery. However, external validation beyond the initial development cohort remains limited. This study aimed to assess the validity and reliability of CELS in a distinct patient population undergoing liver resection for intrahepatic cholangiocarcinoma. Methods The primary objective was to assess the association between CELS and surgery-related mortality. Secondary objectives included 30-day mortality, length of hospital stay (LOS), overall survival, and recurrence-free survival. Predictive performance was evaluated using sensitivity, specificity, accuracy, and receiver operating characteristic curve analyses. Results A total of 227 patients were included in the analysis (CELS-positive: n = 87; CELS-negative: n = 140). A total of 58 minor, 62 major, and 107 extended resections were performed. The 90-day mortality rate (surgery-related mortality) was 8.9% in the overall cohort and 9.6% in the validation cohort. The CELS-positive group was more frequently affected by surgery-related mortality compared to the CELS-negative group (20.7% vs. 3.6%, p < 0.001). CELS demonstrated a sensitivity of 81.8%, a specificity of 66.3%, and an overall accuracy of 67.8% in predicting surgery-related death. The discriminatory ability of CELS was moderate, with an area under the receiver operating characteristic (ROC) curve of 0.74. Conclusions CELS demonstrated moderate predictive ability for surgery-related mortality following liver resection for intrahepatic cholangiocarcinoma.
No takes yet. Share an insight, caveat, or question.
Scholz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: